TREATMENT OF RELAPSED CARCINOMA OF THE OVARY WITH CISPLATIN OR CARBOPLATIN FOLLOWING INITIAL TREATMENT WITH THESE COMPOUNDS
TREATMENT OF RELAPSED CARCINOMA OF THE OVARY WITH CISPLATIN OR CARBOPLATIN FOLLOWING INITIAL TREATMENT WITH THESE COMPOUNDS
复制标题
DOI：
10.1016/0090-8258(90)90174-j
复制
发表时间：
1990-02-01
影响因子：
4.7
通讯作者：
DAWSON, T
中科院分区：
文献类型：
--
作者：
GORE, ME;FRYATT, I;DAWSON, T
54例用顺铂或卡铂达到完全或部分缓解的卵巢癌患者在复发时用相同的药物重新激发或交叉使用其他铂化合物。43例交叉患者中的15例（35%）和1/11例（9%）再激发患者有应答;差异不显著，两组之间的生存期无差异。应答者的生存时间明显长于无应答者（P = 0.001），但对再激发有应答者和对交叉给药有应答者之间的生存期无差异。初始治疗结束和复发之间的无进展间隔是治疗反应和生存的重要预后因素;在18个月前复发的患者中，17%（6/35）有反应，而在18个月后复发的患者中，53%（10/19）有反应中位生存期分别为221天和486天（P = 0.026）。
Fifty-four patients with ovarian cancer who achieved a complete or partial remission with cisplatin or carboplatin were rechallenged with the same drug or crossed over to the other platinum compound at relapse. Fifteen of 43 (35%) crossover patients and 1/11 (9%) rechallenged patients responded; the difference was not significant and there was no difference in survival between the two groups. Responders survived significantly longer than nonresponders (P = 0.001) but there was no survival difference between those who responded to a rechallenge and those who responded to crossing to the other platinum compound. The progression-free interval between the end of initial treatment and relapse was a significant prognostic factor for response to treatment and survival; 17% (6/35) of patients who relapsed before 18 months responded as compared to 53% (10/19) who relapsed after 18 months (P = 0.006) and median survival was 221 and 486 days, respectively, for these two groups (P = 0.026).